Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Nab-paclitaxel Plus Gemcitabine · 1 trial · 1 indication
Duration from the date of initial treatment to the date of death due to any cause
| Arm | Type | Description |
|---|---|---|
| Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine | EXPERIMENTAL | - |
| Nab-paclitaxel Plus Gemcitabine | ACTIVE_COMPARATOR | - |
| Surufatinib with Nab-paclitaxel, and Gemcitabine | OTHER | - |
| Name | Type | Description |
|---|---|---|
| Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine | DRUG | Drug: Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine 1. Surufatinib: 200mg, qd 2. Camrelizumab: 200mg, IV drip, Q3W, D1 3. Nab-paclitaxel: 125 mg/m2, IV drip, D1,D8 4. Gemcitabine : 1000 mg/m2, IV drip, D1, D8 |
| Nab-paclitaxel Plus Gemcitabine | DRUG | Drug: Nab-paclitaxel Plus Gemcitabine 1. Nab-paclitaxel: 125 mg/m2, IV drip, D1,D8 2. Gemcitabine : 1000 mg/m2, IV drip, D1, D8 |
| Surufatinib with Nab-paclitaxel, and Gemcitabine | DRUG | Drug: Surufatinib with Nab-paclitaxel, and Gemcitabine 1. Surufatinib: 200mg, qd 2. Nab-paclitaxel: 125 mg/m2, IV drip, D1,D8 3. Gemcitabine : 1000 mg/m2, IV drip, D1, D8 |
Inclusion Criteria: 1. Fully understand and voluntarily sign an informed consent form, willing and able to follow the study process; 2. Age range is 18-75 years old (inclusive); 3. Pancreatic cancer confirmed by histology or cytology; 4. Stage IV metastasis Pancreatic cancer patients; 5. Have not r...
Top 20 of 73 competitors